MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Reviewed for Re-release: February 15, 2018
Date of Original Release: June 16, 2016
Date Credit Expires: February 15, 2020

Learning Objectives

At the conclusion of this course, participants should be able to:

• Recognize the impact of depression and anxiety in Parkinson's disease.
• Identify the symptoms of depression and anxiety in Parkinson's.
• Discuss the underlying causes (both psychological and neurochemical factors) of depression and anxiety in Parkinson's disease.
• Summarize the current medication treatments of depression and anxiety in Parkinson's disease as well as strategies for patients and family members to manage symptoms.
• Describe ongoing research efforts into depression and anxiety in Parkinson's disease and why these endeavors are important.

Target Audience

This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty

Gregory Pontone, MD
Director, Parkinson's Neuropsychiatry Clinical Programs
Johns Hopkins University School of Medicine
Disclosures: Expert Testimony to Allergan Inc., Material Support from UCB (drug rotigotine and placebo supplied for NIH-funded study)

Laura Marsh, MD
Executive Director of the Mental Health Service
Michael E. DeBakey Veterans Affairs Medical Center
Nothing to disclose

Israel Robledo
Person with Parkinson's
Nothing to disclose

Dave Iverson
Moderator

Nothing to disclose